506943 Stock Overview
Manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
J. B. Chemicals & Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,715.00 |
| 52 Week High | ₹2,029.00 |
| 52 Week Low | ₹1,376.95 |
| Beta | -0.016 |
| 11 Month Change | -9.66% |
| 3 Month Change | -8.98% |
| 1 Year Change | 19.14% |
| 33 Year Change | 111.77% |
| 5 Year Change | 766.82% |
| Change since IPO | 67,287.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 506943 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.5% | -0.2% | 0.3% |
| 1Y | 19.1% | 40.5% | 27.3% |
Return vs Industry: 506943 underperformed the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: 506943 underperformed the Indian Market which returned 27.3% over the past year.
Price Volatility
| 506943 volatility | |
|---|---|
| 506943 Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 506943 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 506943's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 5,311 | Nikhil Chopra | www.jbpharma.com |
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms.
J. B. Chemicals & Pharmaceuticals Limited Fundamentals Summary
| 506943 fundamental statistics | |
|---|---|
| Market cap | ₹258.74b |
| Earnings (TTM) | ₹6.11b |
| Revenue (TTM) | ₹37.11b |
43.6x
P/E Ratio7.2x
P/S RatioIs 506943 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 506943 income statement (TTM) | |
|---|---|
| Revenue | ₹37.11b |
| Cost of Revenue | ₹12.84b |
| Gross Profit | ₹24.27b |
| Other Expenses | ₹18.16b |
| Earnings | ₹6.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 39.35 |
| Gross Margin | 65.40% |
| Net Profit Margin | 16.47% |
| Debt/Equity Ratio | 2.5% |
How did 506943 perform over the long term?
See historical performance and comparison